Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of some unusual options trading on Wednesday. Stock investors purchased 1,002 put options on the stock. This represents an increase of 1,791% compared to the average volume of 53 put options.

Maravai LifeSciences Stock Performance

NASDAQ MRVI traded down $0.16 on Thursday, hitting $3.66. The stock had a trading volume of 344,568 shares, compared to its average volume of 1,128,547. The company’s 50-day moving average is $3.46 and its two-hundred day moving average is $3.23. The stock has a market cap of $935.90 million, a price-to-earnings ratio of -4.07 and a beta of 0.38. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. Maravai LifeSciences has a one year low of $1.66 and a one year high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. The business had revenue of $49.87 million for the quarter, compared to analysts’ expectations of $49.06 million. On average, analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wells Fargo & Company lifted their price target on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $4.86.

Insider Activity

In other Maravai LifeSciences news, Director Gregory T. Lucier acquired 48,528 shares of the stock in a transaction dated Monday, December 8th. The stock was acquired at an average price of $3.67 per share, with a total value of $178,097.76. Following the completion of the transaction, the director directly owned 155,123 shares in the company, valued at approximately $569,301.41. This trade represents a 45.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 2.11% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds have recently modified their holdings of MRVI. T. Rowe Price Investment Management Inc. grew its stake in shares of Maravai LifeSciences by 2.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock valued at $20,595,000 after buying an additional 178,445 shares in the last quarter. Mackenzie Financial Corp grew its position in Maravai LifeSciences by 1.7% in the fourth quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock worth $20,148,000 after acquiring an additional 104,355 shares in the last quarter. Mirabella Financial Services LLP grew its position in Maravai LifeSciences by 0.3% in the second quarter. Mirabella Financial Services LLP now owns 3,750,000 shares of the company’s stock worth $9,038,000 after acquiring an additional 10,049 shares in the last quarter. Monaco Asset Management SAM increased its stake in shares of Maravai LifeSciences by 315.0% during the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after purchasing an additional 2,775,372 shares during the last quarter. Finally, Tejara Capital Ltd raised its holdings in shares of Maravai LifeSciences by 23.1% during the 4th quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock valued at $9,816,000 after purchasing an additional 566,768 shares in the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.